FrancophonIA/ELRC3.0 huggingface dataset:
English: If the ANC decreases to < 1.0 x 109/L during the treatment period the dose of filgrastim should be re-escalated according to the above steps
Croatian: Smanji li se ABN tijekom trajanja terapije na < 1,0 x 109/l, dozu filgrastima treba ponovno povećavati u skladu s gornjom shemom.
English: Talk to your doctor, pharmacist or nurse before using Ratiograstim.
Croatian: Upozorenja i mjere opreza Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primijenite Ratiograstim.
English: Check the appearance of Ratiograstim.
Croatian: 4. Provjerite izgled lijeka Ratiograstim.
English: You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea
Croatian: Morate reći svom liječniku prije nego primite ovaj lijek ako Vi (ili Vaše dijete) imate(ima) nasljedno nepodnošenje fruktoze ili ako Vaše dijete više ne može konzumirati slatku hranu ili piće zbog pojave mučnine, povraćanja ili neugodnih nuspojava poput nadutosti, grčeva u trbuhu ili proljeva.
English: How is Ratiograstim given and much should I take?
Croatian: Kako se Ratiograstim primjenjuje i koliko Ratiograstima moram uzeti?
English: Ratiograstim does not contain any preservative.
Croatian: Ratiograstim ne sadrži konzervanse.
English: Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post marketing experience.
Croatian: Reakcije preosjetljivosti, uključujući anafilaksiju, osip, urtikariju, angioedem, dispneju i hipotenziju, na početku liječenja ili kasnije tijekom liječenja prijavljene su u kliničkim ispitivanjima te nakon stavljanja lijeka u promet.
English: Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals.
Croatian: Ispitivanja filgrastima u bolesnika s teškim oštećenjem funkcije bubrega ili jetre pokazuju da mu je farmakokinetički i farmakodinamički profil sličan onome u zdravih osoba.
English: The recommended starting dose of filgrastim is 0.1 MIU (1 μg)/kg/day with titration up to a maximum of 0.4 MIU (4 μg)/kg/day until a normal neutrophil count is reached and can be maintained (ANC > 2.0 x 109/L).
Croatian: Preporučena početna doza je 0,1 MIU (1 μg)/kg/dan i može se titrirati do najviše 0,4 MIU (4 μg)/kg/dan, do postizanja normalnog broja neutrofila, koji će biti moguće i održavati (ABN > 2,0 x 109/l).
English: Aspartate aminotransf erase increased Gammaglutamyl transferase increased
Croatian: Povišena aspartat aminotransferaza Povišena gama glutamiltransfera za
English: You will need to take Ratiograstim until your white blood cell count is normal.
Croatian: Ratiograstim ćete morati uzimati dok se broj Vaših leukocita ne vrati u normalu.
English: In most cases aortitis was diagnosed by CT scan and generally resolved after withdrawal of G-CSF.
Croatian: U većini slučajeva aortitis je dijagnosticiran CT snimkom i uglavnom se povukao nakon prestanka primjene G-CSF-a (vidjeti također dio 4.8).
English: Ratiograstim contains sorbitol
Croatian: Ratiograstim sadrži sorbitol
English: Take your Ratiograstim pre-filled syringe out of the refrigerator.
Croatian: 2. Uzmite napunjenu štrcaljku lijeka Ratiograstim iz hladnjaka.
English: Myelodysplastic syndrome or Chronic myeloid leukemia
Croatian: Mijelodisplastični sindrom ili kronična mijeloična leukemija
English: Ratiograstim should not be diluted with sodium chloride solution.
Croatian: Ratiograstim se ne smije razrjeđivati s otopinom natrijeva klorida.
English: • increase in white blood cells (leukocytosis)
Croatian: • porast broja bijelih krvnih stanica (leukocitoza)
English: Transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim administration and leukapheresis was observed in 35 % of subjects studied.
Croatian: Prolazna trombocitopenija (trombociti < 100 x 109/l) nakon primjene filgrastima i leukafereze zabilježena je u 35 % ispitanika.
English: As a result of the potential to receive higher doses or a greater number of these medicinal products with filgrastim therapy, the patient may be at higher risk of developing thrombocytopenia and anaemia.
Croatian: Kao rezultat mogućnosti da se uz liječenje filgrastimom prime više doze ili veći broj tih lijekova, bolesnik može biti izložen većem riziku od trombocitopenije i anemije.
English: Filgrastim may be given as a 30 minute or 24 hour intravenous infusion or given by continuous 24 hour subcutaneous infusion.
Croatian: Filgrastim se može davati kao 30-minutna ili 24-satna intravenska infuzija ili kao neprekidna 24-satna supkutana infuzija.
English: Capillary leak syndrome which can be life threatening if treatment is delayed, has been reported after G-CSF administration and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration.
Croatian: Sindrom povećane propusnosti kapilara, koji može ugrožavati život ako se ne počne liječiti na vrijeme, zabilježen je nakon primjene G-CSF-a, a karakterizira ga hipotenzija, hipoalbuminemija, edem i hemokoncentracija.
English: A meta-analysis of allogeneic transplant studies, including the results of nine prospective randomized trials, 8 retrospective studies and 1 case-controlled study, did not detect an effect on the risks of acute GvHD, chronic GvHD or early treatment-related mortality.
Croatian: Meta analizom studija alogenih presađivanja, uključujući rezultate devet prospektivnih randomiziranih istraživanja, osam retrospektivnih studija te jedne studije istraživanja parova nisu pronađeni učinci na rizik od razvoja akutnog GvHD-a, kao i kroničnog GvHD-a ili rane smrtnosti povezane s terapijom.
English: Special caution should be used when treating patients with high dose chemotherapy because improved tumour outcome has not been demonstrated and intensified doses of chemotherapeutic agents may lead to increased toxicities including cardiac, pulmonary, neurologic and dermatologic effects (please refer to the Summary of Product Characteristics of the specific chemotherapy agents used).
Croatian: Nužan je poseban oprez pri liječenju bolesnika visokim dozama kemoterapeutika jer nije dokazano da se time postiže povoljniji ishod, a povišenje doze može dovesti do povećanja toksičnosti, uključujući učinke na srce, pluća, živčani sustav i kožu (pogledati sažetak opisa svojstava lijeka za pojedini kemoterapeutik koji se koristi).
English: Teva Santé Tél: +33 1 55 91 78 00
Croatian: Tél: +33 1 55 91 78 00
English: Ratiograstim stimulates the bone marrow to produce new white cells quickly.
Croatian: Ratiograstim stimulira koštanu srž da brže proizvodi nove bijele stanice.
English: The subcutaneous route is preferred in most cases.
Croatian: U većini slučajeva prednost se daje supkutanom putu primjene.
English: Leukocytosis (WBC > 50 x 109/l) was observed in 41% of normal donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).
Croatian: Leukocitoza (broj bijelih krvnih stanica > 50 x 109/l) uočena je u 41 % zdravih davatelja, a prolazna trombocitopenija (trombociti < 100 x 109/l) u 35 % davatelja nakon primjene filgrastima i leukafereze (vidjeti dio 4.4).
English: • swelling and/or fluid in the lungs (pulmonary oedema)
Croatian: • oticanje i/ili nakupljanje tekućine u plućima (plućni edem)
English: Some cytotoxic agents exhibit particular toxicities to the haematopoietic progenitor pool and may adversely affect progenitor mobilisation.
Croatian: Neki citotoksični lijekovi osobito su toksični za progenitorske stanice periferne krvi i mogu štetno utjecati na njihovu mobilizaciju.
English: Example: In a final injection volume of 20 mL, total doses of filgrastim less than 30 MIU (300 μg) should be given with 0.2 mL of 200 mg/mL (20 %) human albumin solution added.
Croatian: Primjer: U konačni volumen injekcije od 20 ml s ukupnom dozom filgrastima manjom od 30 MIU (300 μg), treba dodati 0,2 ml otopine ljudskog albumina čija je koncentracija 200 mg/ml (20 %).
English: The recommended starting dose is 1.2 MIU (12 μg)/kg/day as a single dose or in divided doses.
Croatian: Preporučena početna doza je 1,2 MIU (12 μg)/kg/dan, u jednokratnoj ili u podijeljenim dozama.
English: It is recommended that the ANC is measured daily for the first 2 to 3 days of filgrastim administration.
Croatian: Preporučuje se tijekom prva 2 do 3 dana primjene filgrastima određivati ABN svakodnevno.
English: As with other haematopoietic growth factors, G-CSF has shown in vitro stimulating properties on human endothelial cells.
Croatian: Pokazalo se da G-CSF, kao i ostali hematopoetski faktori rasta, stimulira ljudske endotelne stanice in vitro.
English: Filgrastim had no observed effect on the fertility of male or female rats.
Croatian: Nema uočenog učinka filgrastima na plodnost mužjaka ili ženki štakora.
English: In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Ratiograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Croatian: U bolesnika, djece i odraslih, s teškom kongenitalnom cikličkom ili idiopatskom neutropenijom i apsolutnim brojem neutrofila (ABN) ≤ 0,5 x 109/l, kao i s teškim ili rekurentnim infekcijama u anamnezi, dugotrajna primjena Ratiograstim se koristi za povećanje broja neutrofila i za smanjenje incidencije i skraćivanje trajanja događaja povezanih s infekcijama.
English: The no observed adverse effect level for embryo-foetal toxicity in this study was 10 µg/kg/day, which corresponded to a systemic exposure of approximately 3-5 times the exposures observed in patients treated with the clinical dose.
Croatian: U ovom ispitivanju doza od 10 µg/kg/dan bila je razina pri kojoj nisu uočeni štetni učinci za embrio-fetalnu toksičnost, što odgovara sistemskoj izloženosti od oko 3-5 puta izloženosti uočene u bolesnika liječenih s kliničkim dozama.
English: - if you get left upper belly (abdominal) pain, pain below the left rib cage or pain at the tip of your shoulder, as there may be a problem with your spleen (enlargement of the spleen (splenomegaly) or rupture of the spleen).
Croatian: - ako osjetite bol u gornjem lijevom dijelu trbuha (abdomena), bol na lijevoj strani ispod rebara ili bol pri vrhu ramena, jer možete imati problem sa slezenom (uvećanje slezene (splenomegalija) ili puknuće (ruptura) slezene).
English: Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than 1.5 x 109/L.
Croatian: Filgrastim treba davati svakodnevno u supkutanim injekcijama, sve dok broj neutrofila ne dosegne 1,5 x 109/l i dok se ne bude održavao na toj ili višoj vrijednosti.
English: In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section
Croatian: U kliničkim ispitivanjima te u razdoblju nakon stavljanja lijeka u promet prijavljene su plućne nuspojave, uključujući intersticijsku bolest pluća, plućni edem i plućne infiltracije, u nekim slučajevima s posljedičnim respiratornim zatajenjem ili sindromom akutnog respiratornog distresa (ARDS), koji mogu imati smrtni ishod (vidjeti dio 4.4).
English: There have been reports of graft versus host disease (GvHD) and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.8 and 5.1).
Croatian: Postoje izvještaji o bolesti presatka protiv primatelja (engl. graft versus host disease, GvHD) te smrtnim ishodima u bolesnika koji su nakon alogene transplantacije koštane srži dobivali G-CSF (vidjeti dijelove 4.8 i 5.1).
English: The most serious adverse reactions that may occur during filgrastim treatment include: anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease.
Croatian: Najozbiljnije nuspojave koje se mogu pojaviti tijekom liječenja filgrastimom uključuju: anafilaktičku reakciju, ozbiljne štetne plućne događaje (uključujući intersticijsku pneumoniju i sindrom akutnog respiratornog distresa), sindrom povećane propusnosti kapilara, tešku splenomegaliju/rupturu slezene, pretvorbu u mijelodisplastični sindrom ili leukemiju u bolesnika s teškom kroničnom neutropenijom, bolest presatka protiv primatelja (GvHD) u bolesnika podvrgnutih alogenoj transplantaciji koštane srži ili transplantaciji krvotvornih matičnih stanica periferne krvi te krizu srpastih stanica u bolesnika s bolešću srpastih stanica.
English: What you need to know before you use Ratiograstim Do not use Ratiograstim
Croatian: Što morate znati prije nego počnete primjenjivati Ratiograstim
English: Contents of the pack and other information Information for injecting yourself
Croatian: Sadržaj pakiranja i druge informacije Informacije za samostalno injiciranje Sljedeće informacije namijenjene su samo za zdravstvene radnike
English: A subset of approximately 12 % of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation.
Croatian: U oko 12 % bolesnika s urednim citogenetskim nalazom prije početka primjene lijeka kasnije su, pri rutinskim kontrolama, nađene abnormalnosti, uključujući monosomiju
English: The recommended dose of filgrastim for PBPC mobilisation after myelosuppressive chemotherapy is 0.5 MIU (5 μg)/kg/day from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.
Croatian: Preporučena doza za mobilizaciju progenitorskih stanica periferne krvi nakon mijelosupresijske kemoterapije je 0,5 MIU (5 μg)/kg/dan od prvog dana po okončanju kemoterapije do prolaska očekivanog najmanjeg broja neutrofila i do normalizacije njihova broja.
English: In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship.
Croatian: U nekim slučajevima simptomi su se ponavljali pri ponovnom uvođenju lijeka (rechallenge-u), što upućuje na uzročno-posljedičnu povezanost.
English: • severe pain in the bones, chest, gut or joints (sickle cell anaemia with crisis)
Croatian: • jaka bol u kostima, prsnom košu, crijevima ili zglobovima (anemija srpastih stanica s krizom)
English: • changes in blood chemistry
Croatian: • promjene rezultata krvnih pretraga
English: It is currently unclear whether long-term treatment of patients with SCN will predispose patients to cytogenetic abnormalities, MDS or leukaemic transformation.
Croatian: Za sada nije jasno može li dugotrajna primjena u bolesnika s teškom kroničnom neutropenijom stvoriti predispoziciju za citogenetske poremećaje, MDS ili leukemijsku pretvorbu.
English: Infections and
Croatian: Infekcije i infestacije
English: • abnormal x-rays of the lungs (lung infiltration)
Croatian: • abnormalni nalazi rendgenskog snimanja pluća (infiltracija pluća)
English: Dizziness may occur following the administration of filgrastim (see section 4.8).
Croatian: Nakon primjene filgrastima može se javiti omaglica (vidjeti dio 4.8).
English: (mucosal inflammation)
Croatian: (poremećaji volumena tekućine)
English: Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.
Croatian: Zdravi davatelj nema izravne kliničke koristi od mobilizacije progenitorskih stanica periferne krvi, stoga taj postupak treba razmatrati samo u svrhu alogenog presađivanja matičnih stanica.
English: Ratiograstim is one of a group of products that stimulate the production of white blood cells.
Croatian: Ratiograstim je jedan iz skupine lijekova koji potiču stvaranje bijelih krvnih stanica.
English: If you have any of the following or combination of the following side effects: swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness.
Croatian: - ako imate bilo koju od sljedećih nuspojava ili njihovu kombinaciju: oticanje ili podbuhlost koji mogu biti povezani s rjeđim mokrenjem, otežano disanje, oticanje trbuha i osjećaj punoće te opći osjećaj umora.
English: EU/1/08/444/003 2 x 5 pre-filled syringes
Croatian: EU/1/08/444/003 2 x 5 napunjenih štrcaljki
English: In patients undergoing a stem cell or bone marrow transplant, Graft versus host disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.
Croatian: U bolesnika koji se podvrgavaju transplantaciji matičnih stanica ili koštane srži može se javiti bolest presatka protiv primatelja (engl. graft versus host disease, GvHD) - to je reakcija stanica davatelja protiv bolesnika koji prima presadak, čiji znakovi i simptomi uključuju osip na dlanovima ili tabanima te vrijedove i rane u ustima, crijevima, jetri, koži ili na očima, plućima, vagini i zglobovima.
English: Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥ 20 µg/kg/day) and slightly reduced survival rate (100 µg/kg/day).
Croatian: pokazuje kašnjenje u vanjskoj diferencijaciji i retardaciju rasta (≥ 20 µg/kg/dan) te nešto nižu stopu preživljenja (100 µg/kg/dan).
English: If required, Ratiograstim may be diluted in glucose 50 mg/mL (5 %) solution for infusion.
Croatian: Po potrebi, Ratiograstim se može razrijediti u 5% -tnoj otopini glukoze za infuziju (50 mg/ml).
English: Physicians should use caution when prescribing filgrastim in patients with sickle cell trait or sickle cell disease.
Croatian: Liječnici trebaju s oprezom propisivati filgrastim u bolesnika s nasljednim obilježjem srpastih stanica ili bolešću srpastih stanica.
English: • soreness and swelling of the digestive tract lining which runs from the mouth to the anus
Croatian: • bolovi i oticanje sluznice probavnog trakta od usta do anusa (upala sluznice)
English: In clinical studies, dosing with 30 MIU (300 μg)/day on 1 to 7 days per week was required to maintain the ANC > 2.0 x 109/L, with the median dose frequency being 3 days per week.
Croatian: U kliničkim je ispitivanjima za održavanje ukupnog broja neutrofila na vrijednostima > 2,0 x 109/l trebala doza od 30 MIU (300 μg)/dan tijekom 1 do 7 dana na tjedan, a medijan učestalosti doza iznosio je 3 dana na tjedan.
English: The first dose of filgrastim should be administered at least 24 hours after cytotoxic chemotherapy.
Croatian: Prva doza filgrastima smije se dati najmanje 24 sata nakon citotoksične kemoterapije.
English: Ratiograstim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
Croatian: Ratiograstim je indiciran za skraćivanje trajanja neutropenije i smanjenje incidencije febrilne neutropenije u bolesnika s malignim bolestima koji se liječe citotoksičnom kemoterapijom (osim kronične mijeloične leukemije i mijelodisplastičnih sindroma) i za skraćivanje trajanja neutropenije u bolesnika koji su prije presađivanja koštane srži primili mijeloablacijsku terapiju, izloženih povećanom riziku od produljene, teške neutropenije.
English: Permanently discontinue Ratiograstim in patients with clinically significant hypersensitivity.
Croatian: Liječenje Ratiograstimom mora se trajno prekinuti u bolesnika u kojih se razvije klinički značajna preosjetljivost.
English: However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy.
Croatian: No, sa stajališta mogućih rizika povezanih s teškom leukocitozom, pri liječenju filgrastimom valja redovito, u određenim vremenskim razmacima, provjeravati broj leukocita.
English: There were no differences in the safety profiles for paediatric patients treated for SCN.
Croatian: Nije bilo razlika u profilu sigurnosti primjene u odnosu na bolesnike liječene zbog teške kronične neutropenije.
English: Alopeciaa
Croatian: Alopecijaa
English: Cases of decreased bone density and osteoporosis have been reported in paediatric patients with SCN receiving chronic treatment with filgrastim.
Croatian: Slučajevi smanjene gustoće kostiju i osteoporoze zabilježeni su u pedijatrijskih bolesnika s teškom kroničnom neutropenijom koji primaju kronično liječenje filgrastimom.
English: Do not administer filgrastim to patients with a history of hypersensitivity to filgrastim or pegfilgrastim
Croatian: Filgrastim se ne smije primjenjivati u bolesnika s anamnezom preosjetljivosti na filgrastim ili pegfilgrastim.
English: The recommended starting dose of filgrastim is 1.0 MIU (10 μg)/kg/day.
Croatian: Preporučena dnevna doza filgrastima je 1,0 MIU (10 μg)/kg/dan.
English: The first dose of filgrastim should be administered at least 24 hours after cytotoxic chemotherapy and at least 24 hours after bone marrow infusion.
Croatian: Prvu dozu filgrastima treba dati najmanje 24 sata nakon citotoksične kemoterapije i najmanje 24 sata nakon infuzije koštane srži.
English: The recommended starting dose is 0.5 MIU (5 μg)/kg/day as a single dose or in divided doses.
Croatian: Preporučena početna doza je 0,5 MIU (5 μg)/kg/dan, u jednokratnoj ili u podijeljenim dozama.
English: Initial dose adjustment to alternate day dosing with 30 MIU (300 μg)/day is recommended.
Croatian: Preporučuje se početno prilagođavanje doze na 30 MIU (300 μg) svaki drugi dan.
English: Rare (may affect up to 1 in 1,000 people):
Croatian: Rijetko (mogu se javiti do 1 na 1000 osoba):
English: Filgrastim should be diluted in 20 mL of 5% glucose solution for infusion (see section 6.6).
Croatian: Filgrastim treba razrijediti u 20 ml 5%-tne otopine glukoze za infuziju (vidjeti dio 6.6).
English: Ratiograstim is supplied in packs of 1, 5 or 10 pre-filled syringes or multipacks of 10 (2 packs of 5) pre-filled syringes.
Croatian: Ratiograstim je dostupan u pakiranju od 1, 5 ili 10 napunjenih štrcaljki ili u višestrukom pakiranju od 10 (2 pakiranja od 5) napunjenih štrcaljki.
English: Special care should be taken in the diagnosis of SCNs to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia and myeloid leukaemia.
Croatian: Pri dijagnosticiranju teške kronične neutropenije nužan je poseban oprez kako bi ih se razlikovalo od drugih hematopoetskih poremećaja poput aplastične anemije, mijelodisplazije i mijeloične leukemije.
English: Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient abnormal bone scans This should be considered when interpreting bone-imaging results.
Croatian: Pojačana krvotvorna aktivnost koštane srži kao odgovor na terapiju faktorom rasta povezana je s prolaznim abnormalnim nalazima slikovnih pretraga kostiju.
English: Oropharyng eal paina,e
Croatian: Orofaringealna bola,e